EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, BioCryst Pharmaceuticals's Enterprise Value is MXN54,677 Mil.
BioCryst Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was MXN5,634 Mil. Therefore, BioCryst Pharmaceuticals's EV-to-FCF for today is 9.70.
The historical rank and industry rank for BioCryst Pharmaceuticals's EV-to-FCF or its related term are showing as below:
MEX:BCRX'
s EV-to-FCF Range Over the Past 10 Years
Min: -106.99 Med: -10.57 Max: 152.84
Current: 10.05
During the past 13 years, the highest EV-to-FCF of BioCryst Pharmaceuticals was 152.84. The lowest was -106.99. And the median was -10.57.
MEX:BCRX's EV-to-FCF is ranked better than 77.86% of 560
companies
in the Drug Manufacturers industry
Industry Median: 20.52
vs MEX:BCRX: 10.05
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
BioCryst Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
BioCryst Pharmaceuticals's share price for today is MXN175.00.
BioCryst Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-31.227.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
BioCryst Pharmaceuticals EV-to-FCF Related Terms
BioCryst Pharmaceuticals EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, BioCryst Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioCryst Pharmaceuticals EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BioCryst Pharmaceuticals's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where BioCryst Pharmaceuticals's EV-to-FCF falls into.
BioCryst Pharmaceuticals's current Enterprise Value is MXN54,677 Mil.
BioCryst Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN5,634 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioCryst Pharmaceuticals (MEX:BCRX) has a EV-to-FCF of 9.70 as of Jul. 01, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on BioCryst Pharmaceuticals and its competitors. According to the industry distribution chart, BioCryst Pharmaceuticals ranks #124 out of 560 companies in the Drug Manufacturers industry, placing it in the top 22.1%.
Is BioCryst Pharmaceuticals' EV-to-FCF too high?
BioCryst Pharmaceuticals' current EV-to-FCF is 9.70. The Drug Manufacturers industry median EV-to-FCF is 20.52. BioCryst Pharmaceuticals' value of 9.70 is 52.7% below this industry median. Based on the distribution chart, BioCryst Pharmaceuticals ranks #124 out of 560 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, BioCryst Pharmaceuticals has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioCryst Pharmaceuticals' EV-to-FCF compare to SUPN and PBH?
According to the Drug Manufacturers industry distribution chart, BioCryst Pharmaceuticals ranks #124 out of 560 companies for EV-to-FCF. This places BioCryst Pharmaceuticals in the top 22% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 20.52. BioCryst Pharmaceuticals' value of 9.70 is 52.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.52, based on 560 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioCryst Pharmaceuticals's current EV-to-FCF of 9.70 is 52.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on BioCryst Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioCryst Pharmaceuticals's current EV-to-FCF is 9.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioCryst Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, BioCryst Pharmaceuticals (MEX:BCRX) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN222.30, compared to a current price of MXN175.00 — trading 21.3% below its estimated fair value. The current EV-to-FCF is 9.70 and 52.7% below the Drug Manufacturers industry median of 20.52. BioCryst Pharmaceuticals' overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For BioCryst Pharmaceuticals (MEX:BCRX), the current EV-to-FCF is 9.70 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioCryst Pharmaceuticals (MEX:BCRX) Overvalued in 2026?
Based on GuruFocus' analysis, BioCryst Pharmaceuticals stock appears to be undervalued.
The current stock price of MXN175.00 is trading 21.3% below its estimated GF Value™ of MXN222.30.
GuruFocus considers BioCryst Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for MEX:BCRX:
EV-to-FCF: 9.70
GF Value™: MXN222.30 vs. price of MXN175.00 (21.3% below fair value)
Industry Position: 52.7% below the Drug Manufacturers median (#124 of 560)
No single metric tells the full story. See the MEX:BCRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
58GF Score
Get the complete analysis for MEX:BCRX
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:BCRX has been successfully added to your 
